Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
UCB Pharma (Germany)
h-index: 64
Total citations: 17,550
Total papers: 807
Homepage:
https://www.ucb.de/
Recent papers from UCB Pharma (Germany)
Adjunctive Brivaracetam in Early Treatment Line Combinations: 12-Month Real-World Experience and Impact on Health Outcomes in Adult Patients with Focal Seizures
Drugs - Real World Outcomes · 2026
Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study
Rheumatology and Therapy · 2026
Planning and performing CT-guided interventions for source control in septic patients: a survey by the European Society of Emergency Radiology
Insights into Imaging · 2026
Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension
Arthritis & Rheumatology · 2026
Quantification of intervertebral disc degeneration using dual-energy computed tomography collagen maps: a comparative study with MRI Pfirrmann grading
Scientific Reports · 2026
The Patient Experience of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Post-Diagnosis: Results from an International Survey
Neurology and Therapy · 2026
Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness
Epilepsia · 2026
Measurement properties of the FATIGUE-PRO in patients with SLE in real-world settings
Lupus Science & Medicine · 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies
The Journal of Rheumatology · 2026
Loss of Productivity, Seizure Worry, and Patient and Caregiver Quality of Life Associated with Prolonged Seizures: Results from a Global Real-world Point-in-time Study (P4-11.008)
Neurology · 2026
Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset
Brain Communications · 2026
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2026
Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study
Journal of Orthopaedic Translation · 2026
Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions
Therapeutic Advances in Neurological Disorders · 2026
Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial
EULAR Rheumatology Open · 2026
A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson’s Disease Community
Neurology and Therapy · 2026
P179 Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study
Lara D. Veeken · 2026
Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis
Neurology and Therapy · 2026
Bioequivalence and Safety Assessment of Brivaracetam Dry Syrup Compared With Tablets in Healthy Japanese Participants: Results From Two Randomized Single‐ and Multiple‐Dose Trials
Clinical Pharmacology in Drug Development · 2026
Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non‐Biologic Treatment: Results From an Overlap Weighting Analysis in High‐Risk Patients With Axial Spondyloarthritis
International Journal of Rheumatic Diseases · 2026